четверг, 18 августа 2016 г.

Mizuho Reaffirms Underperform Rating for Valeant Pharmaceuticals International Inc.

Mizuho Reaffirms Underperform Rating for Valeant Pharmaceuticals International Inc.


's stock had its "underperform" rating restated by analysts at Mizuho in a note issued to investors on Thursday. They currently have a $11.00 price objective on the specialty pharmaceutical company's stock.



from Biotech News